Biomarker Clinical Phase Outsourcing Services Global Market Report 2025

Description

Biomarker clinical phase outsourcing services involve contracting specialized firms or organizations to handle various aspects of clinical trials related to biomarkers. Biomarkers are measurable indicators of biological states or conditions, commonly utilized in medical research and clinical trials to evaluate the effectiveness or safety of drugs or treatments.

The primary types of biomarker clinical phase outsourcing services include surrogate endpoints, predictive biomarkers, prognostic biomarkers, safety biomarkers, and others. Surrogate endpoints serve as biomarkers intended to substitute for a clinical endpoint. Outsourcing services utilize surrogate endpoints to streamline clinical trials by providing early indications of efficacy, reducing trial duration, and potentially accelerating regulatory approvals. Service types such as biomarker validation, biomarker testing services, and biomarker sample analysis cater to therapeutic areas including oncology, neurology, cardiology, autoimmune diseases, and others. The end users typically include pharmaceutical companies, biotechnology companies, as well as academic and research institutions.

The biomarker clinical phase outsourcing services market research report is one of a series of new reports from The Business Research Company that provides biomarker clinical phase outsourcing services market statistics, including biomarker clinical phase outsourcing services industry global market size, regional shares, competitors with an biomarker clinical phase outsourcing services market share, detailed biomarker clinical phase outsourcing services market segments, market trends and opportunities, and any further data you may need to thrive in the biomarker clinical phase outsourcing services industry. This biomarker clinical phase outsourcing services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biomarker clinical phase outsourcing services market size has grown exponentially in recent years. It will grow from $9.71 billion in 2024 to $11.94 billion in 2025 at a compound annual growth rate (CAGR) of 23.0%. The growth in the historic period can be attributed to rising government initiatives and funding, increasing diagnostic applications of biomarkers, a rise in R&D funding from the government, rapid advancements in technologies such as genomics, proteomics, and imaging, and the increasing demand for cancer biomarkers.

The biomarker clinical phase outsourcing services market size is expected to see exponential growth in the next few years. It will grow to $27.09 billion in 2029 at a compound annual growth rate (CAGR) of 22.7%. The growth in the forecast period can be attributed to the increasing use of biomarkers in the various phases of clinical trials, the use of biomarkers in clinical trials continues to expand, as does the growing demand for precision medicines, the rising adoption of companion diagnostics, and the and the increasing demand for personalized medicine. Major trends in the forecast period include advanced parameters in the trials, diagnostic-focused clinical phases, rapid advancements in biomarker technology, rising government initiatives and funding, and advancements in technology.

The anticipated increase in clinical trials is set to drive the growth of the biomarker clinical phase outsourcing services market in the future. Clinical trials involve research studies conducted with human participants to assess the safety and effectiveness of new medical treatments, interventions, or diagnostic methods. This surge in clinical trials is facilitated by advancements in medical research, the growing prevalence of chronic diseases, augmented funding from governmental and private sources, and the rising demand for innovative treatments and therapies. Outsourcing providers often possess specialized knowledge and expertise in biomarker discovery, validation, and analysis, which can enhance the quality and reliability of biomarker data collected during trials. For example, data from the United States National Library of Medicine in May 2023 revealed an increase in registered clinical trials from 399,499 in 2022 to 437,533 across all 50 states and 221 countries. Additionally, the report indicated that 140,492 studies (31%) were registered in the United States alone, while 241,498 studies (53%) were recorded in non-U.S. locations. Therefore, the rise in clinical trials is expected to propel the growth of the biomarker clinical phase outsourcing services market.

Key players in the biomarker clinical phase outsourcing services market are concentrating on advancements in high-throughput flow cytometry and ELISpot testing to gain a competitive advantage. These technologies are utilized for biomarker analysis, providing rapid and precise assessment of immune responses and cellular markers. For instance, in November 2022, Celerion Inc., a U.S.-based biotechnology outsourcing services company, broadened its service portfolio to encompass GLP/GCP-compliant molecular and cell biology testing. This strategic expansion aims to bolster Celerion's capabilities in supporting clients throughout the drug development process, from early clinical research to regulatory submissions. By adding GLP/GCP-compliant molecular and cell biology tests, such as pharmacokinetic (PK), pharmacodynamic (PD), and biomarker analysis, Celerion can offer a more comprehensive range of services to assist clients in generating high-quality data meeting regulatory standards, thereby expediting the development of new medicines.

In March 2023, SSI Strategy, a US-based life sciences consulting firm, partnered with Koneksa, a US-based health technology company specializing in digital biomarkers and clinical research. This collaboration aims to enhance patient monitoring and streamline research processes, enabling pharmaceutical and biotech companies to gain deeper insights and accelerate the development of new therapies. The partnership focuses on advancing the use of real-world and remote monitoring technologies to support more efficient and patient-centered clinical studies.

Major companies operating in the biomarker clinical phase outsourcing services market are Thermo Fisher Scientific Inc., Labcorp Drug Development Inc., ICON plc, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Syneos Health Inc., Intertek Group plc, Charles River Laboratories International Inc., Parexel International Corporation, QIAGEN N.V., Medpace Inc., Bioclinica Inc., Evotec SE, GenScript Biotech Corporation, Precision for Medicine Inc., BioAgilytix Labs LLC, Celerion Inc., Frontage Laboratories Inc., SomaLogic Inc., Selvita S.A., BioIVT LLC, Discovery Life Sciences LLC, Metabolon Inc., Caprion Proteomics Inc., Canopy Biosciences LLC

North America was the largest region in the biomarker clinical phase outsourcing services market in 2024. The regions covered in the biomarker clinical phase outsourcing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the biomarker clinical phase outsourcing services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The biomarker clinical phase outsourcing services market includes revenues earned by entities by consulting services, diagnostic tests, clinical trial design, and biomarker sample analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biomarker Clinical Phase Outsourcing Services Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biomarker clinical phase outsourcing services market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biomarker clinical phase outsourcing services ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biomarker clinical phase outsourcing services market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Surrogate Endpoints; Predictive Biomarker; Prognostic Biomarker; Safety Biomarker; Other Biomarker Types
2) By Service Type: Biomarker Validation; Biomarker Testing Services; Biomarker Sample Analysis
3) By Therapeutic Area: Oncology; Neurology; Cardiology; Autoimmune Diseases; Other Therapeutic Areas
4) By End-User: Pharmaceutical Companies; Biotechnology Companies; Academic And Research Institutions
Subsegments:
1) By Surrogate Endpoints: Tumor Marker-Based Endpoints; Imaging-Based Endpoints; Genetic or Genomic Markers
2) By Predictive Biomarker: Genetic Predictive Biomarkers; Protein Predictive Biomarkers; Metabolomic Predictive Biomarkers
3) By Prognostic Biomarker: Cancer Prognostic Biomarkers; Cardiovascular Prognostic Biomarkers; Neurological Prognostic Biomarkers
4) By Safety Biomarker: Toxicity Biomarkers; Adverse Drug Reaction Biomarkers; Drug Interaction Biomarkers
5) By Other Biomarker Types: Inflammation Biomarkers; Infectious Disease Biomarkers; Autoimmune Disease Biomarkers
Companies Mentioned: Thermo Fisher Scientific Inc.; Labcorp Drug Development Inc.; ICON plc; Eurofins Scientific SE; WuXi AppTec Co. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r29604

1. Executive Summary

2. Biomarker Clinical Phase Outsourcing Services Market Characteristics

3. Biomarker Clinical Phase Outsourcing Services Market Trends And Strategies

4. Biomarker Clinical Phase Outsourcing Services Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Biomarker Clinical Phase Outsourcing Services Growth Analysis And Strategic Analysis Framework

5.1. Global Biomarker Clinical Phase Outsourcing Services PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Biomarker Clinical Phase Outsourcing Services Market Growth Rate Analysis
5.4. Global Biomarker Clinical Phase Outsourcing Services Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Biomarker Clinical Phase Outsourcing Services Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Biomarker Clinical Phase Outsourcing Services Total Addressable Market (TAM)

6. Biomarker Clinical Phase Outsourcing Services Market Segmentation

6.1. Global Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Surrogate Endpoints
Predictive Biomarker
Prognostic Biomarker
Safety Biomarker
Other Biomarker Types
6.2. Global Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Biomarker Validation
Biomarker Testing Services
Biomarker Sample Analysis
6.3. Global Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oncology
Neurology
Cardiology
Autoimmune Diseases
Other Therapeutic Areas
6.4. Global Biomarker Clinical Phase Outsourcing Services Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmaceutical Companies
Biotechnology Companies
Academic And Research Institutions
6.5. Global Biomarker Clinical Phase Outsourcing Services Market, Sub-Segmentation Of Surrogate Endpoints, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tumor Marker-Based Endpoints
Imaging-Based Endpoints
Genetic Or Genomic Markers
6.6. Global Biomarker Clinical Phase Outsourcing Services Market, Sub-Segmentation Of Predictive Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Genetic Predictive Biomarkers
Protein Predictive Biomarkers
Metabolomic Predictive Biomarkers
6.7. Global Biomarker Clinical Phase Outsourcing Services Market, Sub-Segmentation Of Prognostic Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cancer Prognostic Biomarkers
Cardiovascular Prognostic Biomarkers
Neurological Prognostic Biomarkers
6.8. Global Biomarker Clinical Phase Outsourcing Services Market, Sub-Segmentation Of Safety Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Toxicity Biomarkers
Adverse Drug Reaction Biomarkers
Drug Interaction Biomarkers
6.9. Global Biomarker Clinical Phase Outsourcing Services Market, Sub-Segmentation Of Other Biomarker Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Inflammation Biomarkers
Infectious Disease Biomarkers
Autoimmune Disease Biomarkers

7. Biomarker Clinical Phase Outsourcing Services Market Regional And Country Analysis

7.1. Global Biomarker Clinical Phase Outsourcing Services Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Biomarker Clinical Phase Outsourcing Services Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market

8.1. Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biomarker Clinical Phase Outsourcing Services Market

9.1. China Biomarker Clinical Phase Outsourcing Services Market Overview
9.2. China Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biomarker Clinical Phase Outsourcing Services Market

10.1. India Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biomarker Clinical Phase Outsourcing Services Market

11.1. Japan Biomarker Clinical Phase Outsourcing Services Market Overview
11.2. Japan Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biomarker Clinical Phase Outsourcing Services Market

12.1. Australia Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biomarker Clinical Phase Outsourcing Services Market

13.1. Indonesia Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biomarker Clinical Phase Outsourcing Services Market

14.1. South Korea Biomarker Clinical Phase Outsourcing Services Market Overview
14.2. South Korea Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biomarker Clinical Phase Outsourcing Services Market

15.1. Western Europe Biomarker Clinical Phase Outsourcing Services Market Overview
15.2. Western Europe Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biomarker Clinical Phase Outsourcing Services Market

16.1. UK Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biomarker Clinical Phase Outsourcing Services Market

17.1. Germany Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biomarker Clinical Phase Outsourcing Services Market

18.1. France Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biomarker Clinical Phase Outsourcing Services Market

19.1. Italy Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biomarker Clinical Phase Outsourcing Services Market

20.1. Spain Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biomarker Clinical Phase Outsourcing Services Market

21.1. Eastern Europe Biomarker Clinical Phase Outsourcing Services Market Overview
21.2. Eastern Europe Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biomarker Clinical Phase Outsourcing Services Market

22.1. Russia Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biomarker Clinical Phase Outsourcing Services Market

23.1. North America Biomarker Clinical Phase Outsourcing Services Market Overview
23.2. North America Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biomarker Clinical Phase Outsourcing Services Market

24.1. USA Biomarker Clinical Phase Outsourcing Services Market Overview
24.2. USA Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biomarker Clinical Phase Outsourcing Services Market

25.1. Canada Biomarker Clinical Phase Outsourcing Services Market Overview
25.2. Canada Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biomarker Clinical Phase Outsourcing Services Market

26.1. South America Biomarker Clinical Phase Outsourcing Services Market Overview
26.2. South America Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biomarker Clinical Phase Outsourcing Services Market

27.1. Brazil Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biomarker Clinical Phase Outsourcing Services Market

28.1. Middle East Biomarker Clinical Phase Outsourcing Services Market Overview
28.2. Middle East Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biomarker Clinical Phase Outsourcing Services Market

29.1. Africa Biomarker Clinical Phase Outsourcing Services Market Overview
29.2. Africa Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Biomarker Clinical Phase Outsourcing Services Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biomarker Clinical Phase Outsourcing Services Market Competitive Landscape And Company Profiles

30.1. Biomarker Clinical Phase Outsourcing Services Market Competitive Landscape
30.2. Biomarker Clinical Phase Outsourcing Services Market Company Profiles
- 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Labcorp Drug Development Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. ICON plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Eurofins Scientific SE Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. WuXi AppTec Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Biomarker Clinical Phase Outsourcing Services Market Other Major And Innovative Companies

31.1. Syneos Health Inc.
31.2. Intertek Group plc
31.3. Charles River Laboratories International Inc.
31.4. Parexel International Corporation
31.5. QIAGEN N.V.
31.6. Medpace Inc.
31.7. Bioclinica Inc.
31.8. Evotec SE
31.9. GenScript Biotech Corporation
31.10. Precision for Medicine Inc.
31.11. BioAgilytix Labs LLC
31.12. Celerion Inc.
31.13. Frontage Laboratories Inc.
31.14. SomaLogic Inc.
31.15. Selvita S.A.

32. Global Biomarker Clinical Phase Outsourcing Services Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biomarker Clinical Phase Outsourcing Services Market

34. Recent Developments In The Biomarker Clinical Phase Outsourcing Services Market

35. Biomarker Clinical Phase Outsourcing Services Market High Potential Countries, Segments and Strategies

35.1 Biomarker Clinical Phase Outsourcing Services Market In 2029 - Countries Offering Most New Opportunities
35.2 Biomarker Clinical Phase Outsourcing Services Market In 2029 - Segments Offering Most New Opportunities
35.3 Biomarker Clinical Phase Outsourcing Services Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer